SCHEMBL1484077

SCHEMBL1484077

C=CC(=O)OCC(CCCCC)CCCCC

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 8/20 0.78
HPGD P15428 1/20 0.56
CYP3A4 P08684 4/20 0.45
ATM Q13315 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
ALDH1A1 P00352 4/20 0.42
THRB P10828 1/20 0.41
HCAR2 Q8TDS4 2/20 0.40
CA2 P00918 1/20 0.40
ZDHHC7 Q9NXF8 1/20 0.40
LMNA P02545 1/20 0.39
TP53 P04637 2/20 0.39
HIF1A Q16665 2/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL731685 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL729461 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL731397 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL17851227 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL729056 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL1897662 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL17851220 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL729433 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL731354 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1
SCHEMBL17851210 0.98 TSHR (0.76) TSHRHPGDCYP3A4ATMTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242548-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-08-03 US disclosed
EP-2295479-B1 COPOLYMER, METHOD FOR PRODUCING THE SAME, OIL REPELLENT COMPOSITION AND ARTICLE PROCESSED WITH THE OIL REPELLENT COMPOSITION ASAHI GLASS CO LTD (JP) 2015-02-11 EP disclosed
US-8431664-B2 Copolymer, method for its production, oil repellent composition and article treated therewith ASAHI GLASS COMPANY, LIMITED (JP) 2013-04-30 US disclosed
US-20110077349-A1 COPOLYMER, METHOD FOR ITS PRODUCTION, OIL REPELLENT COMPOSITION AND ARTICLE TREATED THEREWITH ASAHI GLASS COMPANY, LIMITED (JP) 2011-03-31 US disclosed
EP-2295479-A1 COPOLYMER, METHOD FOR PRODUCING THE SAME, OIL REPELLENT COMPOSITION AND ARTICLE PROCESSED WITH THE OIL REPELLENT COMPOSITION Asahi Glass Company, Limited (JP) 2011-03-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242548-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER KRAS, HRAS, NRAS TSHR 4752/4885HPGD 1795/4885CYP3A4 4840/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.